Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C ...

The compelling clinical activity, durable response and acceptable tolerability profile seen with elironrasib underscore the potential of this differentiated RAS (ON) G12C-selective inhibitor, ...
Medscape

Defining the COX Inhibitor Selectivity of NSAIDs: Implications for Understanding Toxicity

All NSAIDs variably inhibit COX-1 and COX-2 and the mechanisms of inhibition fall into three broad categories, although there are exceptions. For example, nimesulide is a weak competitive inhibitor of ...
The Globe and Mail

PCSK9 Inhibitors Market Analysis 2034 – Competitive Landscape, Clinical Trials, Market Share, Medication, Patient Population, Companies by DelveInsight

In 2023, the 7MM (seven major markets) PCSK9 inhibitors market was valued at approximately USD 2 billion, with the United States leading at around USD 900 million. That year, roughly 640,000 cases of ...